$16.48
2.92% today
Nasdaq, Nov 20, 08:47 pm CET
ISIN
US0231112063
Symbol
AMRN

Amarin Corporation Plc Sponsored ADR Stock price

$16.98
-3.27 16.15% 1M
+6.08 55.78% 6M
+7.28 75.05% YTD
+7.17 73.02% 1Y
-6.02 26.17% 3Y
-73.82 81.30% 5Y
-23.02 57.55% 10Y
-213.02 92.62% 20Y
Nasdaq, Closing price Wed, Nov 19 2025
+0.27 1.62%
ISIN
US0231112063
Symbol
AMRN
Industry

Key metrics

Basic
Market capitalization
$347.5m
Enterprise Value
$61.0m
Net debt
positive
Cash
$286.6m
Shares outstanding
20.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.5 | 1.5
EV/Sales
0.3 | 0.3
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
70.9%
Return on Equity
-16.9%
ROCE
-6.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$226.7m | $226.8m
EBITDA
$-25.6m | $-52.9m
EBIT
$-28.7m | $-52.9m
Net Income
$-86.6m | $-45.6m
Free Cash Flow
$-21.6m
Growth (TTM | estimate)
Revenue
-5.9% | -0.8%
EBITDA
37.1% | -1.1%
EBIT
34.4% | 4.4%
Net Income
-120.8% | 44.5%
Free Cash Flow
-12.5%
Margin (TTM | estimate)
Gross
55.0%
EBITDA
-11.3% | -23.3%
EBIT
-12.7%
Net
-38.2% | -20.1%
Free Cash Flow
-9.5%
More
EPS
$-0.2
FCF per Share
$-1.0
Short interest
2.6%
Employees
275
Rev per Employee
$830.0k
Show more

Is Amarin Corporation Plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Amarin Corporation Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Amarin Corporation Plc Sponsored ADR forecast:

3x Hold
38%
5x Sell
63%

Analyst Opinions

8 Analysts have issued a Amarin Corporation Plc Sponsored ADR forecast:

Hold
38%
Sell
63%

Financial data from Amarin Corporation Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
227 227
6% 6%
100%
- Direct Costs 102 102
3% 3%
45%
125 125
8% 8%
55%
- Selling and Administrative Expenses 132 132
17% 17%
58%
- Research and Development Expense 20 20
1% 1%
9%
-26 -26
37% 37%
-11%
- Depreciation and Amortization 3.07 3.07
2% 2%
1%
EBIT (Operating Income) EBIT -29 -29
34% 34%
-13%
Net Profit -87 -87
121% 121%
-38%

In millions USD.

Don't miss a Thing! We will send you all news about Amarin Corporation Plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amarin Corporation Plc Sponsored ADR Stock News

Neutral
GlobeNewsWire
11 days ago
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the importance of guidel...
Neutral
GlobeNewsWire
17 days ago
DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new findings at the American Heart Association's Scientific Sessions 2025 scheduled for November 7-10 in New Orleans, Louisiana. These new data supported by Amarin will further reinforce ...
Neutral
Seeking Alpha
22 days ago
Amarin Corporation plc ( AMRN ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Aaron Berg - CEO, President & Director Peter Fishman - Senior VP & CFO Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Mazahir Alimohamed - Leerink Partners LLC, Research Division Presentation Operator Welcome to Amarin Corporation's conference call to discus...
More Amarin Corporation Plc Sponsored ADR News

Company Profile

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Head office United Kingdom
CEO Aaron Berg
Employees 275
Founded 1989
Website amarincorp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today